Role of the angiotensin II type 2 receptor in arterial remodeling after wire injury in mice

Hypertension Research

Volumn 31, Issue 6, 2008, Pages 1241-1249

  Yamamoto, Yoshiyuki ^a   Watari, Yuichiro ^a   Brydun, Andrei ^a   Yoshizumi, Masao ^a   Akishita, Masahiro ^b   Horiuchi, Masatsugu ^c   Chayama, Kazuaki ^a   Oshima, Tetsuya ^a   Ozono, Ryoji ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 2; Receptor; Restenosis; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BIOTIN; DNA NUCLEOTIDYLEXOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; INTIMA; KNOCKOUT MOUSE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE INFLAMMATION; PROTEIN FUNCTION; RESTENOSIS; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; APOPTOSIS; ARTERIES; CELL PROLIFERATION; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; RECEPTOR, ANGIOTENSIN, TYPE 2; TUNICA INTIMA; TUNICA MEDIA;

EID: 48349143351     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1241     Document Type: Article

References (28)

1. Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 1949-1952.
2. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
3. Peters S, Trummel M, Meyners W, Koehler B, Westermann K: Valsaltan versus ACE inhibition after bare metal stent implantation-results of the VALVACE trial. Int J Cardiol 2005; 98: 331-335.
4. Harada K, Komuro I, Sugaya T, Murakami K, Yazaki Y: Vascular injury causes neointimal formation in angiotensin type 1a receptor knockout mice. Circ Res 1999; 84: 179-185.
5. Brede M, Hadamek K, Meinel L, et al: Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT2 receptor. Circulation 2001; 104: 2602-2607.
6. Nakajima M, Hutchinson HG, Fujinaga M, et al: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene tmnsfer. Proc Natl Acad Sci U S A 1995; 92: 10663-10667.
7. Stoll M, Steckelingl UM, Paul M, Bottan SP, Metzger R, Unger T: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
8. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T: Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 2003; 26: 89-95.
9. Kurisu S, Ozono R, Oshima T, et al: Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41: 99-107.
10. Suzuki J, Iwai M, Nakagami H, et al: Role of angiotensin II regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 2002; 106: 847-853.
11. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ: Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022-19026.
12. Lehtonen JYA, Horiuchi M, Daviet L, Akishita M, Dzau VJ: Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 1998; 274: 16901-16906.
13. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996; 93: 156-160.
14. Wang LX, Ideishi M, Yahiro E, Urata H, Arakawa K, Saku K: Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res 2001; 24: 179-187.
15. Lévy BI: Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the rennin-angiotensin system. Circulation 2004; 109: 8-13.
16. Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T: AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post myocardial infarction remodeling. Life Sci 2006; 80: 82-88.
17. Oishi Y, Ozono R, Yano Y, et al: Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 2003; 41: 814-818.
18. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-747.
19. Sata M, Maejima Y, Adachi F, et al: A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointima hyperplasia. J Mol Cell Cardiol 2000; 32: 2097-2104.
20. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 1992; 86: 100-110.
21. Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25: 362-369.
22. Meurice T, Banters C, Hermant X, et al: Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomized, double-blind, placebo-controlled trial. Lancet 2001; 357: 1321-1324.
23. Sata M, Sugiura S, Yoshizumi M, Ouchi Y, Hirata Y, Nagai R: Acute and chronic smooth muscle cell apoptosis after mechanical vascular injury can occur independently of the Fas-death pathway. Atheroscler Thromb Vasc Biol 2001; 21: 1733-1737.
24. Akishita M, Horiuchii M, Yamada H, et al: Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2000; 2: 13-20.
25. Tanaka K, Sata M, Hirata Y, Nagai R: Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res 2003; 93: 783-790.
26. Hilgers KF, Veelken R, Muller DN, et al: Renin uptake by endothelium mediates vascular angiotensin formation. Hypertension 2001; 38: 243-248.
27. Perlman H, Maillard L, Krasinski K, Walsh K: Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997; 95: 981-987.
28. Pollman MJ, Hall JL, Gibbons GH: Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury: Influence of redox state and cell phenotype. Circ Res 1999; 84: 113-121.